Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients with Non-Small Cell Lung Cancer who have Progressive Disease after Treatment with Tyrosine Kinase Inhibitors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genmab
• Treatments: Antibodies, Monoclonal; Zalutumumab

Criteria

Inclusion Criteria:

• Patients must have documented disease progression after TKI treatment (verified by CT scan and/or MRI according to RECIST).

Exclusion Criteria:

• Estimated life expectancy of less than 3 months.

• Received the following treatments within 2 weeks prior to Visit 2:

• Cytotoxic or cytostatic anti-cancer chemotherapy

• Total resection or irradiation of the target lesion

• Any investigational agent